Viewing data from:

IMIQUIMOD

ANDA

IMIQUIMOD | A205971 | TARO PHARMACEUTICAL INDUSTRIES LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: ZYCLARA(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$111.43

per gm

Lowest NADAC/Unit

$36.38

per gm

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
51672417409IMIQUIMOD 3.75% CREAM PUMP	$111.43	GM	Generic	—	2026-06-17
51672417406IMIQUIMOD 3.75% CREAM	$36.38	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$728.97

Highest Price

$728.97

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
51672-4174-06IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM	$728.97	FSS	Golden State Medical Supply, Inc.	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain11 active DMFs4 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

TARO PHARMACEUTICAL INDUSTRIES LTDIMIQUIMOD USP

DMF 180312005

TAPI NL BVIMIQUIMOD

DMF 187822005

WAVELENGTH ENTERPRISES LTDIMIQUIMOD

DMF 190092005

TEVA PHARMACEUTICAL INDUSTRIES LTDIMIQUIMOD

DMF 195072006

ALIVUS LIFE SCIENCES LTDIMIQUIMOD USP

DMF 197352006

INTERQUIM SAIMIQUIMOD

DMF 202472007

USV PRIVATE LTDIMIQUIMOD USP

DMF 203532007

ACTAVIS GROUP PTC EHFIMIQUIMOD USP [NON-STERILE DRUG SUBSTANCE]

DMF 216102008

SOLARA ACTIVE PHARMA SCIENCES LTDIMIQUIMOD

DMF 221592008

WANBURY LTDIMIQUIMOD

DMF 320172017

TARO PHARMACEUTICAL INDUSTRIES LTDIMIQUIMOD, USP (NEW ROS)

DMF 390042024

TAI HENG INDUSTRY CO LTDInactiveIMIQUIMOD

DMF 202562007

AMINO CHEMICALS LTDInactiveIMIQUIMOD

DMF 207362007

CHEMWERTH INCInactiveIMIQUIMOD, NON-STERILE BULK DRUG SUBSTANCE

DMF 209312007

CIPLA LTDInactiveIMIQUIMOD

DMF 219272008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Feb 2, 2021	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 3.75%

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Jan 26, 2021

No patent or exclusivity listings for this strength.